扶正化积方剂对H22肝癌小鼠抑瘤的作用
作者:
基金项目:

解放军第302医院院长创新基金(YNKT2013026)。


Experimental study of Fuzheng Huaji decoction inhibition effect on H22 tumor bearing mice
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [12]
  • |
  • 相似文献
  • |
  • 引证文献
  • | |
  • 文章评论
    摘要:

    目的 研究扶正化积方(FZHJF)对小鼠H22肝癌移植瘤的抑制作用及对免疫功能的影响。方法 建立小鼠皮下H22移植性肝癌模型,随机分为模型对照组、FZHJF低、中、高剂量组(4.55、13.65、40.95 g/kg)和5-氟尿嘧啶组(0.2 mL/10 g),连续给药12 d后,采集肿瘤与脏器称重并计算抑瘤率、肝脏指数、脾脏指数和胸腺指数;同时对各组肿瘤外观和肿瘤病理进行分析。结果 肿瘤病理结果显示均为典型的肝细胞癌。FZHJF剂量组的瘤重显著低于模型对照组(P<0.05),FZHJF的抑瘤率随剂量升高而增加,高剂量组的抑瘤率(49.02%)接近5-FU组(51.51%);肿瘤外观图显示FZHJF从低剂量至高剂量组的肿瘤体积呈现逐渐减小的趋势,且均小于模型对照组。FZHJF各剂量组的脾脏指数与胸腺指数均显著高于模型对照组与5-FU组(P<0.05)。结论 FZHJF对H22肝癌移植瘤具有显著的抑制作用和免疫增强作用,为今后临床研究提供了试验数据。

    Abstract:

    Objective To study the anti-tumor and immune effects of FZHJF on H22 liver cancer-bearing mice.Methods The H22 transplanted mouse models were established and randomly divided into five groups:model group,low-,medium-and high-dose FZHJF(4.55,13.65,40.95g/kg)and 5-Fu groups(0.2mL/10g).12 days after treatment,the tumor inhibitory rate,liver index,thymus index,spleen index were calculated.At the same time,the appearance of liver tumor and tumor pathology in different groups was analyzed.Results Pathology results confirmed the tumors were hepatocelluar carcinoma.Tumor weight in FZHJF groups were lower than those of the model group(P<0.05);the tumor inhibitory rate increased with the dosage,and the tumor inhibitory rate in high dose group(49.02%)closed to 5-Fu group(51.51%);the results of tumor appearance showed that the tumor volume have the trend of reduce gradually,and is smaller than the control group.Thymus index and spleen index in FZHJF groups were markedly higher than those of the model and 5-FU groups(P<0.05).Conclusion FZHJF has significant anti-tumor effect on transplanted H22 tumor in mice and has the function of immunological enhancement,and these results will provide theoretical foundation for clinical practice of FZHJF.

    参考文献
    [1] 黄展,辛华,江旭东,等.独角莲醇提液对H22肝癌荷瘤小鼠血清IL-2和TNF-α水平的影响[J].肿瘤药学,2013,3(6):432-435.
    [2] Forner A,Llovet JM,Bruix J.Hepatocellular carcinoma[J].Lancet,2012,379(9822):1245-1255.
    [3] Cao H,Phan H,Yang LX.Improved chemotherapy for hepatocellular carcinoma[J].Anticancer Res,2012,32(4):1379-1386.
    [4] 李晓娟,靳雪源,白冰珂,等.PLCε基因敲除小鼠移植性肝癌模型的建立与分析[J].中国比较医学杂志,2014,24(4):5-7.
    [5] Qi F,Li A,Inagaki Y,et al.Chinese herbal medicines as adjuvant treatment during chemo-or radio-therapy for cancer[J].Biosci Trends,2010,4(6):297-307.
    [6] 李晓娟,张巧云,李蓓,等.BALB/c突变卷毛小鼠部分生长发育指标初探[J].中国比较医学杂志,2013,23(11):36-39.
    [7] 胡陵静,王怀碧,张国铎.原发性肝癌的中医治疗现状[J].中国中医急症,2013,22(2):273-275.
    [8] 邢风举,李柳,周仲瑛.周仲瑛教授应用复法大方治疗肝癌[J].吉林中医药,2014,34(1):22-25.
    [9] 何仁强,李配富,张宁,等.扶正化毒消癌方干预原发性肝癌中晚期患者36例[J].中国实验方剂学杂志,2013,19(24):296-300.
    [10] 苑静波,苏春芝,李光荣,等.扶正健脾中药对介入治疗后肝癌患者相关指标影响观察[J].辽宁中医杂志,2011,38(10):2027-2028.
    [11] 李晓晶,王爱洁.白花蛇舌草和半枝莲微粉配伍对H22肝癌小鼠抑瘤作用的实验研究[J].江苏中医药,2013,45(7):66-68.
    [12] 蔡鹏,王建国,杨士勇,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].中国肿瘤临床与康复,2007,14(2):142.
    相似文献
    引证文献
引用本文

李晓娟,白云峰,王睿林,邬顺全,侯俊,李瑞生.扶正化积方剂对H22肝癌小鼠抑瘤的作用[J].中国比较医学杂志,2015,25(11):42~45.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 最后修改日期:2015-10-10
  • 在线发布日期: 2015-12-02
防诈骗提示!请勿点击不明链接或添加个人微信。编辑部所有邮箱后缀均为@cnilas.org
关闭